Neurodegeneration and the Cathepsin Family
Antibody resources for cathepsin family proteinases in lysosomal storage disorders, neurodegeneration, and aging.
Lysosomal cathepsins represent a family of proteolytic enzymes critical to cellular protein turnover, antigen processing, and tissue remodeling. Dysregulation of cathepsin activity has been implicated in a range of neurodegenerative diseases, from Alzheimer's and Parkinson's to lysosomal storage disorders. Understanding the biochemical diversity within the cathepsin family—and the mechanisms that govern their activation and inhibition—remains a priority for researchers investigating protein aggregation, neuroinflammation, and autophagy-lysosomal dysfunction in the aging brain.1,2
The cathepsin family — three catalytic classes, one lysosomal compartment
The mammalian cathepsin family comprises 15 proteases organized by catalytic mechanism: 11 cysteine cathepsins (B, C, F, H, K, L, O, S, V, W, and Z), two aspartic cathepsins (D and E), and two serine cathepsins (A and G). Despite structural and mechanistic differences, most cathepsins are synthesized as inactive zymogens, trafficked to the endolysosomal system, and activated by proteolytic cleavage in the acidic environment of the lysosome. The exceptions—cathepsin G, which resides primarily in neutrophil azurophilic granules, and cathepsin S, which remains stable at neutral pH—highlight the functional diversity that has evolved within this protease family.
Cysteine cathepsins share a papain-like fold and a conserved catalytic triad. Cathepsin B is unique among them for its exopeptidase activity, mediated by an occluding loop that confers both endo- and carboxydipeptidase function. Aspartic cathepsins D and E operate via a two-aspartate mechanism and are responsible for bulk proteolysis at acidic pH. Serine cathepsins A and G employ a chymotrypsin-like catalytic mechanism but diverge in tissue expression and substrate preference. This mechanistic diversity enables the cathepsin family to process a remarkably broad substrate repertoire within a single organelle.
Cathepsin B and D — the most-studied targets in neurodegeneration
Among the 15 cathepsins, cathepsin B and cathepsin D have received the most attention in neurodegenerative research. Cathepsin B is upregulated in brain tissue from Alzheimer's disease patients and has been shown to cleave amyloid precursor protein (APP) at the β-secretase site, contributing to amyloid-β peptide generation. Conversely, cathepsin B knockout in transgenic mouse models reduces amyloid plaque burden, supporting a pathogenic role for this protease in amyloidogenesis.1
Cathepsin D, the major aspartic endopeptidase of the lysosome, degrades aggregated proteins including α-synuclein, tau, and amyloid-β. Loss-of-function mutations in the cathepsin D gene (CTSD) cause neuronal ceroid lipofuscinosis type 10, a severe lysosomal storage disorder characterized by progressive neurodegeneration and early lethality. Recent work has demonstrated that cathepsin D can also fragment amyloid fibrils, a process that paradoxically accelerates fibril propagation by generating seeds for further aggregation.8 This dual role—degradation versus fragmentation—complicates therapeutic strategies targeting cathepsin D in protein-misfolding diseases.
What is the difference between cathepsin B and cathepsin D?
Cathepsin B is a cysteine protease with both endo- and exopeptidase activity, capable of cleaving peptide bonds within proteins and removing C-terminal dipeptides. Cathepsin D is an aspartic protease that functions exclusively as an endopeptidase, hydrolyzing internal peptide bonds at acidic pH. Both are abundant in lysosomes, but cathepsin B has been implicated in APP processing and amyloid-β generation, whereas cathepsin D primarily degrades aggregated proteins such as α-synuclein and tau. Their distinct catalytic mechanisms require different substrate specificities and inhibitor profiles.
Cathepsin K, L, S — specialized roles beyond the lysosome
Cathepsin K is best known for its role in osteoclast-mediated bone resorption, where it degrades collagen type I in the resorption lacuna. However, cathepsin K is also expressed in microglia and has been detected in human atherosclerotic plaques, suggesting a function in extracellular matrix remodeling during neuroinflammation. Cathepsin L and cathepsin S are distinguished by their stability at neutral pH, which enables activity outside the lysosome. Cathepsin S is constitutively expressed in antigen-presenting cells and is responsible for invariant chain processing during MHC class II antigen presentation. Upregulation of cathepsin S has been observed in activated microglia in models of traumatic brain injury and Alzheimer's disease, where it contributes to neuroinflammatory signaling.2
Cathepsin L cleaves a broad range of substrates including extracellular matrix proteins, transcription factors, and viral envelope proteins. In neurons, cathepsin L participates in the turnover of misfolded proteins via chaperone-mediated autophagy and macroautophagy. Knockout of cathepsin L in mice leads to accumulation of ceroid lipofuscin in neurons, a hallmark of lysosomal dysfunction. These specialized cathepsins thus operate at the interface of proteostasis, immunity, and tissue remodeling in the central nervous system.
Which cathepsins are most relevant to neurodegeneration?
Cathepsins B, D, L, and S are the most extensively studied in neurodegenerative contexts. Cathepsin B contributes to amyloid-β production and is upregulated in Alzheimer's disease. Cathepsin D degrades α-synuclein and tau; loss-of-function mutations cause neuronal ceroid lipofuscinosis. Cathepsin L participates in autophagy and protein quality control. Cathepsin S is expressed in microglia and has been implicated in neuroinflammation. Each plays distinct roles in proteostasis, and their dysregulation is associated with different aspects of neurodegeneration.
Cystatin inhibitors — the matched-pair antibody story
Cystatins are endogenous inhibitors of cysteine cathepsins, forming tight-binding, reversible complexes that regulate protease activity in the extracellular space and intracellular compartments. The cystatin superfamily includes three families: type 1 (stefins A and B, intracellular), type 2 (cystatins C, D, E, F, M, S, and SA, secreted), and type 3 (kininogens, multidomain). Cystatin C is the most abundant extracellular cystatin and inhibits cathepsins B, H, K, L, and S with picomolar affinity. Mutations in the cystatin C gene (CST3) cause hereditary cerebral amyloid angiopathy, characterized by cystatin C amyloid deposition in cerebral vessels and recurrent hemorrhagic stroke.5
Cystatin B (stefin B) is an intracellular inhibitor that protects against aberrant cathepsin activity during lysosomal membrane permeabilization. Loss-of-function mutations in CSTB cause Unverricht-Lundborg disease, a progressive myoclonus epilepsy with neurodegeneration. The balance between cathepsins and cystatins is critical for maintaining lysosomal integrity and preventing uncontrolled proteolysis in the cytosol. Matched-pair detection of cathepsins and their cognate cystatins—for example, cathepsin S with cystatin F—provides insight into the local proteolytic balance in tissue sections and Western blots.
What is cystatin C and how does it relate to cathepsin biology?
Cystatin C is a secreted, 13 kDa cysteine protease inhibitor that regulates the extracellular activity of cathepsins B, H, K, L, and S. It is expressed ubiquitously and is present in cerebrospinal fluid, where it modulates proteolytic activity in the brain parenchyma. Mutations in cystatin C cause hereditary cerebral amyloid angiopathy due to protein aggregation. Cystatin C levels are also used as a biomarker of kidney function and have been associated with risk of cognitive decline, linking cathepsin inhibition to neurodegeneration.
Calpains and calpastatin — calcium-dependent cysteine proteases
Calpains are a distinct family of calcium-activated, non-lysosomal cysteine proteases involved in cytoskeletal remodeling, signal transduction, and apoptosis. Unlike cathepsins, calpains do not operate in acidic compartments and are not synthesized as zymogens. The ubiquitous isoforms—calpain-1 (μ-calpain) and calpain-2 (m-calpain)—require micromolar and millimolar calcium concentrations, respectively, for activation. Tissue-specific isoforms include calpain-3 (skeletal muscle) and calpain-10 (implicated in type 2 diabetes).
Calpain activity is regulated by calpastatin, a specific endogenous inhibitor that binds the catalytic domain and blocks substrate access. Overactivation of calpains has been observed in excitotoxic injury, ischemic stroke, and Alzheimer's disease, where calcium dysregulation leads to uncontrolled proteolysis of cytoskeletal proteins such as spectrin, tau, and MAP2. Calpain-mediated cleavage of tau generates stable truncation products that seed neurofibrillary tangle formation.2 In contrast to cathepsins, which degrade substrates to peptides, calpains perform limited proteolysis that modulates protein function rather than eliminating it.
The small regulatory subunit (CAPNS1) is shared by calpain-1 and calpain-2, while CAPNS2 associates with other family members. Antibodies targeting both large catalytic subunits and small regulatory subunits enable dissection of heterodimer composition and localization in brain tissue.
Neurodegenerative disease links — Alzheimer's, Parkinson's, lysosomal storage disease
Lysosomal dysfunction is a convergent feature of multiple neurodegenerative diseases. In Alzheimer's disease, cathepsin B and D are redistributed from lysosomes to autophagosomes and the cytosol, where they contribute to APP processing and tau cleavage. Lysosomal pH dysregulation impairs cathepsin activation, leading to accumulation of undigested substrates and lipofuscin granules. Restoration of lysosomal acidity using acidic nanoparticles has been shown to rescue cathepsin activity and reduce aggregate burden in cell models.3,4
In Parkinson's disease, mutations in GBA1 (encoding lysosomal glucocerebrosidase) and LRRK2 both impair autophagy-lysosomal function, leading to α-synuclein accumulation. Cathepsin D is a key enzyme responsible for α-synuclein degradation, and reduced cathepsin D activity has been observed in patient-derived neurons carrying GBA1 mutations. Conversely, upregulation of cathepsin D can promote fibril fragmentation, accelerating the spread of pathological α-synuclein species.6,8
Lysosomal storage diseases caused by cathepsin deficiencies—such as cathepsin D deficiency (NCL10), cathepsin K deficiency (pycnodysostosis), and cathepsin A deficiency (galactosialidosis)—result in progressive neurodegeneration due to accumulation of undigested substrates. These monogenic disorders provide definitive evidence that cathepsin function is essential for neuronal survival and highlight the importance of maintaining proteolytic capacity in the aging brain.
Antibody selection — pro vs mature form detection
Cathepsins are synthesized as inactive proenzymes in the endoplasmic reticulum, trafficked through the Golgi to endosomes, and proteolytically activated in the acidic environment of the lysosome. The propeptide serves as both a chaperone and an inhibitor; its removal generates the catalytically active mature enzyme. Detection of pro and mature forms by Western blot or immunohistochemistry provides insight into protease trafficking, activation state, and localization. For example, procathepsin D (~52 kDa) is cleaved to an intermediate form (~48 kDa) and then to the mature heavy and light chains (~34 and 14 kDa). Accumulation of the proform may indicate impaired lysosomal acidification or trafficking defects.
Why use a polyclonal antibody to detect pro vs mature cathepsin forms?
Polyclonal antibodies raised against full-length or large fragments of cathepsins recognize multiple epitopes across the propeptide and mature domains. This enables detection of both the zymogen and processed forms on the same blot, providing information about activation state and trafficking. Monoclonal antibodies, while highly specific, may recognize only a single epitope that is lost upon proteolytic maturation. For research into lysosomal dysfunction, where propeptide processing is often impaired, polyclonal antibodies offer a more comprehensive view of cathepsin biology.
Rabbit polyclonal antibodies also tend to exhibit higher sensitivity in immunohistochemistry due to the polyclonal nature of the immune response, which increases avidity for target antigen in fixed tissue. This is particularly relevant for cathepsins, which are often concentrated in punctate lysosomal structures that require robust signal amplification for visualization.
TPB's cathepsin and cystatin coverage
Triple Point Biologics maintains a catalog of rabbit polyclonal antibodies spanning the cathepsin, cystatin, and calpain families, validated for Western blot. The cathepsin antibody panel includes all 15 family members: cysteine cathepsins (B, C, F, H, K, L, O, S, V, W, and Z), aspartic cathepsins (D and E), and serine cathepsins (A and G). Cystatin antibodies cover the major regulatory proteins (cystatin A, B, C, D, F, M, and SA), and the calpain set includes both ubiquitous and tissue-specific isoforms, plus calpastatin and regulatory subunits.
Related enzymes such as legumain (asparaginyl endopeptidase), an activator of procathepsins, are also available. Legumain is a cysteine protease that processes cathepsins C, H, and L in the endolysosomal system and is upregulated in tumor-associated macrophages and activated microglia.
Working with cathepsin antibodies — IHC, IF, and WB best practices
For Western blot, cathepsins are typically detected in cell lysates prepared under reducing conditions. Procathepsin and mature forms migrate at distinct molecular weights; inclusion of a positive control lysate (e.g., liver for cathepsin D, spleen for cathepsin S) aids in band assignment. Cathepsins are labile and sensitive to autolysis; lysates should be prepared on ice with protease inhibitor cocktails that include E-64 (cysteine cathepsin inhibitor) or pepstatin A (aspartic cathepsin inhibitor) as appropriate.
For immunohistochemistry, cathepsins exhibit punctate lysosomal staining in most cell types. Antigen retrieval with citrate buffer (pH 6.0) or Tris-EDTA (pH 9.0) improves epitope accessibility in formalin-fixed paraffin-embedded tissue. Co-staining with LAMP1 or LAMP2 confirms lysosomal localization. In neurodegenerative tissue, cathepsin immunoreactivity is often elevated in activated microglia and dystrophic neurites surrounding amyloid plaques. Immunofluorescence protocols benefit from inclusion of autofluorescence quenching steps to reduce lipofuscin signal, which is particularly prominent in aged neurons.
Cross-reactivity is predicted based on sequence homology across species. Most TPB cathepsin antibodies recognize human, mouse, and rat orthologs; validation in the species of interest is recommended. For studies of cathepsin secretion or extracellular activity, conditioned media or serum samples can be concentrated by acetone precipitation or ultrafiltration prior to Western blot analysis.
References
- Di Matteo F et al. Targeting Cathepsins in Neurodegeneration: Biochemical Advances. Biomedicines 2025;13(12):3019. PMID: 41463031. DOI: 10.3390/biomedicines13123019.
- Lewandowski D et al. Cathepsins in Neurological Diseases. Int J Mol Sci 2025;26(16):7886. PMID: 40869205. DOI: 10.3390/ijms26167886.
- Li J et al. PLGA nanoparticles restore acidic pH and degradative function to compromised lysosomes with Cy3-labeling providing enhanced tracking to lysosomes. Am J Physiol Cell Physiol 2026. PMID: 41533007. DOI: 10.1152/ajpcell.00494.2025.
- Li J et al. Sustained Lysosomal Delivery of Enhanced Cy3-Labeled Acid Nanoparticles Restores Lysosomal pH in Retinal Pigment Epithelial Cells and Astrocytes. bioRxiv 2025. PMID: 40667189. DOI: 10.1101/2025.06.16.659991.
- Liu X et al. Resveratrol Attenuates CSF Markers of Neurodegeneration and Neuroinflammation in Individuals with Alzheimer's Disease. Int J Mol Sci 2025;26(11):5044. PMID: 40507855. DOI: 10.3390/ijms26115044.
- Zhang H et al. Calcium modulating ligand confers risk for Parkinson's disease and impacts lysosomes. Ann Clin Transl Neurol 2025. PMID: 40053464. DOI: 10.1002/acn3.52286.
- Wallings RL et al. ASO-mediated knock-down of GPNMB in mutant-GRN and in Grn-deficient peripheral myeloid cells disrupts lysosomal function and immune responses. Mol Neurodegener 2025. PMID: 40200337. DOI: 10.1186/s13024-025-00829-w.
- Sulatsky MI et al. From protective enzyme to facilitator of amyloid propagation: Cathepsin D-mediated amyloid fibril fragmentation. Int J Biol Macromol 2025. PMID: 39952498. DOI: 10.1016/j.ijbiomac.2025.140971.